Dexcom (NASDAQ:DXCM) Director Eric Topol sold 20,000 shares of the business’s stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $100.10, for a total value of $2,002,000.00. Following the transaction, the director now owns 3,695 shares in the company, valued at approximately $369,869.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Dexcom opened at $98.53 on Friday, MarketBeat.com reports. Dexcom has a fifty-two week low of $42.62 and a fifty-two week high of $102.10. The company has a current ratio of 5.83, a quick ratio of 5.42 and a debt-to-equity ratio of 0.79. The company has a market cap of $8.70 billion, a price-to-earnings ratio of -169.88 and a beta of -0.01.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) EPS for the quarter, hitting analysts’ consensus estimates of ($0.32). Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The firm had revenue of $184.40 million for the quarter, compared to analysts’ expectations of $172.66 million. During the same period in the previous year, the firm posted ($0.49) EPS. The business’s revenue for the quarter was up 29.6% compared to the same quarter last year. analysts expect that Dexcom will post -0.51 EPS for the current year.
A number of brokerages recently issued reports on DXCM. Piper Jaffray Companies boosted their price target on Dexcom to $116.00 and gave the company an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. upgraded Dexcom from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $80.00 to $115.00 in a report on Friday, June 8th. TheStreet upgraded Dexcom from a “d” rating to a “c-” rating in a report on Thursday, May 10th. Bank of America started coverage on Dexcom in a report on Friday, May 11th. They set a “buy” rating and a $100.00 price target on the stock. Finally, ValuEngine upgraded Dexcom from a “hold” rating to a “buy” rating in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $74.50.
Dexcom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.